Anti-inflammatory Effects of PPAR-γ Agonists Directly Correlate With PPAR-γ Expression During Acute Pancreatitis

Journal of Gastrointestinal Surgery

Volumn 10, Issue 8, 2006, Pages 1120-1130

  Rollins, Michael D ^a   Sudarshan, Sharon ^a   Firpo, Matthew A ^a   Etherington, Brooke H ^a   Hart, Brandon J ^a   Jackson, Heidi H ^a   Jackson, Jeffrey D ^a   Emerson, Lyska L ^a   Yang, David T ^a   Mulvihill, Sean J ^a   Glasgow, Robert E ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

cerulein; inflammation; Pancreatitis; peroxisome proliferator activated receptor

Indexed keywords

15 DEOXYPROSTAGLANDIN J2; 15-DEOXYPROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CERULETIDE; CHROMAN DERIVATIVE; DRUG DERIVATIVE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN D2; TROGLITAZONE; VASODILATOR AGENT;

ACUTE HEMORRHAGIC PANCREATITIS; ANIMAL; ARTICLE; BLOOD; C3H MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG POTENTIATION; FOLLOW UP; GENE EXPRESSION; GENETICS; HOSPITALIZATION; MALE; MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CAERULEIN; CHROMANS; DISEASE MODELS, ANIMAL; FOLLOW-UP STUDIES; GENE EXPRESSION; MALE; MICE; MICE, INBRED C3H; PANCREATITIS, ACUTE NECROTIZING; PPAR GAMMA; PROSTAGLANDIN D2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33748319436     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gassur.2006.04.027     Document Type: Article

References (41)

1. Banks P.A. Practice guidelines in acute pancreatitis. Am J Gastroenterol 92 (1997) 377-386
2. Steer M.L. Pathogenesis of acute pancreatitis. Digestion 58 Suppl. 1 (1997) 46-49
3. Halangk W., Lerch M.M., Brandt-Nedelev B., Roth W., Ruthenbuerger M., Reinheckel T., Domschke W., Lippert H., Peters C., and Deussing J. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 106 (2000) 773-781
4. Lampel M., and Kern H.F. Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue. Virchows Arch A Pathol Anat Histol 373 (1977) 97-117
5. Steer M.L., and Meldolesi J. The cell biology of experimental pancreatitis. N Engl J Med 316 (1987) 144-150
6. Tani S., Otsuki M., Itoh H., Fujii M., Nakamura T., Oka T., and Baba S. Histologic and biochemical alterations in experimental acute pancreatitis induced by supramaximal caerulein stimulation. Int J Pancreatol 2 (1987) 337-348
7. Saluja A.K., and Steer M.L.P. Pathophysiology of pancreatitis. Role of cytokines and other mediators of inflammation. Digestion 60 Suppl. 1 (1999) 27-33
8. Luthen R., Owen R.L., Sarbia M., Grendell J.H., and Niederau C. Premature trypsinogen activation during cerulein pancreatitis in rats occurs inside pancreatic acinar cells. Pancreas 17 (1998) 38-43
9. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
10. Tanaka T., Kohno H., Yoshitani S., Takashima S., Okumura A., Murakami A., and Hosokawa M. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 61 (2001) 2424-2428
11. Nakajima A., Wada K., Miki H., Kubota N., Nakajima N., Terauchi Y., Ohnishi S., Saubermann L.J., Kadowaki T., Blumberg R.S., Nagai R., and Matsuhashi N. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120 (2001) 460-469
12. Cuzzocrea S., Wayman N.S., Mazzon E., Dugo L., Di Paola R., Serraino I., Britti D., Chatterjee P.K., Caputi A.P., and Thiemermann C. The cyclopentenone prostaglandin 15-deoxy-Delta(12, 14)-prostaglandin J (2) attenuates the development of acute and chronic inflammation. Mol Pharmacol 61 (2002) 997-1007
13. Shimizu K., Shiratori K., Hayashi N., Kobayashi M., Fujiwara T., and Horikoshi H. Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis. Pancreas 24 (2002) 184-190
14. van Westerloo D.J., Florquin S., de Boer A.M., Daalhuisen J., de Vos A.F., Bruno M.J., and van der Poll T. Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. Am J Pathol 166 (2005) 721-728
15. Crosby M.B., Svenson J.L., Zhang J., Nicol C.J., Gonzalez F.J., and Gilkeson G.S. Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide. J Pharmacol Exp Ther 312 (2005) 69-76
16. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 (1995) 813-819
17. Straus D.S., Pascual G., Li M., Welch J.S., Ricote M., Hsiang C.H., Sengchanthalangsy L.L., Ghosh G., and Glass C.K. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A 97 (2000) 4844-4849
18. Hashimoto K., Ethridge R.T., Saito H., Rajaraman S., and Evers B.M. The PPARgamma Ligand, 15d-PGJ2, Attenuates the Severity of Cerulein-Induced Acute Pancreatitis. Pancreas 27 (2003) 58-66
19. Cuzzocrea S., Pisano B., Dugo L., Ianaro A., Britti D., Patel N.S., Di Paola R., Genovese T., Di Rosa M., Caputi A.P., and Thiemermann C. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein. Intensive Care Med 30 (2004) 951-956
20. Denham W., Yang J., Fink G., Denham D., Carter G., Ward K., and Norman J. Gene targeting demonstrates additive detrimental effects of interleukin 1 and tumor necrosis factor during pacreatitis. Gastroenterology 113 (1997) 1741-1746
21. Rongione A.J., Kusske A.M., Kwan K., Ashley S.W., Reber H.A., and McFadden D.W. Interleukin 10 reduces the severity of acute pancreatitis in rats. Gastroenterology 112 (1997) 960-967
22. Collin M., Patel N.S., Dugo L., and Thiemermann C. Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta 12, 14 prostaglandin J2 against the multiple organ failure caused by endotoxin. Crit Care Med 32 (2004) 826-831
23. Kaplan J.M., Cook J.A., Hake P.W., O'Connor M., Burroughs T.J., and Zingarelli B. 15-Deoxy-Delta(12, 14)-prostaglandin J(2) (15D-PGJ(2)), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock. Shock 24 (2005) 59-65
24. Katayama K., Wada K., Nakajima A., Mizuguchi H., Hayakawa T., Nakagawa S., Kadowaki T., Nagai R., Kamisaki Y., Blumberg R.S., and Mayumi T. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 124 (2003) 1315-1324
25. Kawahito Y., Kondo M., Tsubouchi Y., Hashiramoto A., Bishop-Bailey D., Inoue K., Kohno M., Yamada R., Hla T., and Sano H. 15-deoxy-delta(12, 14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106 (2000) 189-197
26. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
27. Shiojiri T., Wada K., Nakajima A., Katayama K., Shibuya A., Kudo C., Kadowaki T., Mayumi T., Yura Y., and Kamisaki Y. PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol 448 (2002) 231-238
28. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., Flanigan A., Murthy S., Lazar M.A., and Wu G.D. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104 (1999) 383-389
29. Zingarelli B., Sheehan M., Hake P.W., O'Connor M., Denenberg A., and Cook J.A. Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12, 14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 171 (2003) 6827-6837
30. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270 (1995) 12953-12956
31. Li M., Pascual G., and Glass C.K. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 20 (2000) 4699-4707
32. Chung S.W., Kang B.Y., Kim S.H., Pak Y.K., Cho D., Trinchieri G., and Kim T.S. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J Biol Chem 275 (2000) 32681-32687
33. Yang X.Y., Wang L.H., Chen T., Hodge D.R., Resau J.H., DaSilva L., and Farrar W.L. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 275 (2000) 4541-4544
34. Desreumaux P., Dubuquoy L., Nutten S., Peuchmaur M., Englaro W., Schoonjans K., Derijard B., Desvergne B., Wahli W., Chambon P., Leibowitz M.D., Colombel J.F., and Auwerx J. Attention of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 193 (2001) 827-838
35. Zingarelli B., and Cook J.A. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 23 (2005) 393-399
36. Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., Witztum J.L., Funk C.D., Conrad D., and Glass C.K. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 400 (1999) 378-382
37. Leininger M.T., Portocarrero C.P., and Houseknecht K.L. Peroxisome proliferator-activated receptor gamma 1 expression in porcine white blood cells: dynamic regulation with acute endotoxemia. Biochem Biophys Res Commun 263 (1999) 749-753
38. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J.L., Auwerx J., Palinski W., and Glass C.K. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 95 (1998) 7614-7619
39. Feingold K., Kim M.S., Shigenaga J., Moser A., and Grunfeld C. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab 286 (2004) E201-E207
40. Hill M.R., Young M.D., McCurdy C.M., and Gimble J.M. Decreased expression of murine PPARgamma in adipose tissue during endotoxemia. Endocrinology 138 (1997) 3073-3076
41. Tanaka T., Itoh H., Doi K., Fukunaga Y., Hosoda K., Shintani M., Yamashita J., Chun T.H., Inoue M., Masatsugu K., Sawada N., Saito T., Inoue G., Nishimura H., Yoshimasa Y., and Nakao K. Down regulation of peroxisome proliferator-activated receptorgamma expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia 42 (1999) 702-710